Kornimate/medical-research-clean huggingface dataset:
exparel versus bupivacaine in post-operative pain control

Conditions: Liposomal Bupivacaine

Summary: this is a prospective, randomized study to evaluate anaesthetic parameters, postoperative analgesia and oral analgesic consumption comparing exparel (liposomal bupivacaine) vs. standard bupivacaine

the main purpose of this prospective, randomized study was to evaluate anaesthetic parameters, postoperative analgesia and oral analgesic consumption comparing exparel (liposomal bupivacaine) vs. standard bupivacaine. at the end of the third molar extraction surgical procedure and at least fifteen minutes following the most recent administration of 2% lidocaine with 1:100,000 epinephrine (routine for this procedure), patients will, at random, receive mandibular and maxillary infiltrations with 3ml of 1.3% liposomal bupivacaine (exparel) or with standard 3ml standard bupivacaine. electronic home questionnaires will be completed by the patient following the procedure for 96 hours to evaluate these clinical parameters

Eligibility criteria:
inclusion criteria: * male and nonpregnant female adults (≥18 years of age) with american society of anesthesiologists physical status classification 1, 2, or 3 who were scheduled to undergo bilateral third molar extraction (extraction of all 4 third molars) under local anesthesia and general anesthesia study participants were required to have full or partial bony impaction of both mandibular third molars. exclusion criteria: * history of allergy or contraindication to amide-type local anesthetics, epinephrine, or opioids a history of any disease or condition or recent use of any drug that, in the opinion of the investigator, might increase the risk of surgery or interfere with study evaluations any use of long-acting opioids, nonsteroidal anti-inflammatory drugs, aspirin, or acetaminophen within 3 days before screening or use of opioids within 24 hours of screening patient that is pregnant or suspected to be pregnant adults that cannot speak english, adults that are unable to consent on their own, or persons that are listed as vulnerable individuals will not be part of the study
removal time of urinary catheter after laparoscopic anterior resection of the rectum

Conditions: Rectum Cancer

Summary: traditionally these catheters are retained for 7 days, because a higher incidence of urinary retention is related to early removal of the urinary catheter. however, recently enhanced recovery after surgery presents that urinary catheters placed via the urethra can be withdrawn 48 hours after colon/rectal surgery in patients receiving epidural pain relief，but there is no clear data on the incidence of urine retention.longer retaining time of urethral catheter would induce the urinary tract infection while early removal of urethral catheter is considered to develop acute retention of urine due to lack of sensation when the bladder is full. taking the comfort and mobility for faster rehabilitation of patients into account, the investigators aim at obtain the optimal removal time of urinary catheter after after laparoscopic anterior resection of the rectum

for a better view to avoid accidental trauma and monitoring kidney function during surgery and in the post-surgery period, patients undergoing abdominal operations will usually have a urinary catheter placed in the bladder before the surgery. traditionally these catheters are retained for 7 days, because a higher incidence of urinary retention is related to early removal of the urinary catheter. however, recently enhanced recovery after surgery presents that urinary catheters placed via the urethra can be withdrawn 48 hours after colon/rectal surgery in patients receiving epidural pain relief. longer retaining time of urethral catheter would induce the urinary tract infection while early removal of urethral catheter is considered to develop acute retention of urine due to lack of sensation when the bladder is full. taking the comfort and mobility for faster rehabilitation of patients into account, the investigators aim at obtain the optimal removal time of urinary catheter after after laparoscopic anterior resection of the rectum .

Eligibility criteria:
inclusion criteria: 1. competent to consent to participate in trial 2. patients with rectal cancer who underwent total or tumor-specific-mesorectal excision with colorectal or colonanal anastomosis 3. elective surgery 4. asa classification of 1\~3 5. if male, international prostate symptom score \<20. exclusion criteria: 1. combined pelvic surgery(pelvic lymph node dissection, hysterectomy, salpingo-oophorectomy, posterior vaginectomy, cystectomy, ureteral double-j stenting, ureterectomy, ureteroureterostomy, prostatectomy) 2. postoperative complications with a dindo grade iii or more 3. known urinary disease(end-stage renal disease, benign prostatic hyperplasia, neurogenic bladder, malignancy)

Keywords: laparoscopic mesorectal excision rectal cancer urinary distention
evaluation of the impact of the hl natural, inc. tension relief product

Conditions: Tension; Headache

Summary: the primary hypothesis of the present study is that supplementation with the tension relief test product will reduce the severity of symptoms of a tension headache.

patients will begin taking the capsules at the onset of headache symptoms. onset is defined as the point in time the participant feels that it is necessary to take the test product for relief of symptoms. when the participant decides to take the test product, they will report symptoms in the headache diary prior to taking the product and rate their symptoms on a 10-point mankoski scale. after consuming the product, the participant will complete a mankoski scale at 15 minutes, 30 minutes and 1 hour after taking the product. if needed the participant will be allowed to take alternative medication (alternative treatment) after an hour after taking the product. if alternative medication is taken, the participant will record this in their headache diary.

Eligibility criteria:
inclusion criteria: adult candidates who are in overall good health and who suffer from mild to moderate tension headaches. participants will be deemed to be in good health if they do not report any of the existing medical conditions asked about in the screening questionnaire. exclusion criteria: * those who have been diagnosed with migraine headaches. * those who score between 36-49 or 60-78 on screening questionnaire. * is \< 18 years of age * those who have been diagnosed with fibromyalgia. * women that are pregnant or breastfeeding. * alcohol consumption more than 7 drinks per week or more than 3 drinks per occasion. * routine recreational drug use such as marijuana. * chronic renal disease * chronic liver disease * allergy to any of the following: aspirin or any other product including salicylates, boswellia, feverfew, skullcap, white willow bark, rice hull, or vegetable cellulose. * unable to swallow pills. * unwilling to try test product for relief of pain and tension headache symptoms. * participants who are currently taking any anticoagulation medications daily. (aspirin, warfarin, heparin etc.)
a phase 2 pilot study of apixaban for the prevention of thromboembolic events in patients with advanced (metastatic) cancer

Conditions: Thrombosis; Cancer; Pulmonary Embolism

Summary: the purpose of this study is to learn whether apixaban is well-tolerated and acceptable as anticoagulant therapy, when administered to patients with advanced or metastatic cancer and at increased risk for venous thromboembolic events. demonstration of a favorable benefit:risk profile could lead to significant reduction in this serious and sometimes fatal complication of ongoing cancer and its treatment.


Eligibility criteria:
key inclusion criteria: * recipients of either first- or second-line chemotherapy for advanced or metastatic lung, breast, gastrointestinal, bladder, ovarian, or prostate cancer or myeloma, selected lymphomas, or cancer of unknown origin * able to begin study medication ≤6 weeks of starting either first- or second-line chemotherapy. * expected course of chemotherapy must have been ≥ 90 days after the start of chemotherapy * per protocol amendment 5, patients receiving bevacizumab were eligible to participate, provided that bevacizumab was used for indications approved by local country law key exclusion criteria: * women who are pregnant, breastfeeding * history of deep vein thrombosis or pulmonary embolism * active bleeding or at high risk of bleeding * metastatic brain cancer * familial bleeding diathesis * serious hemorrhage requiring hospitalization, transfusion, or surgical intervention within 4 weeks of study entry * expected survival \<6 months or an eastern cooperative oncology group performance status ≥3. * candidates for bone marrow transplantation within the 12-week treatment period or 30-day follow-up period * uncontrolled hypertension (systolic blood pressure \>200 mm hg and/or diastolic blood pressure \>110 mm hg * coagulopathy (international normalized ratio \>1.5 or platelet count \ 100\*10\^9/l before starting study medication * one or more of the following: alanine aminotransferase \>3 times the upper limit of normal (uln), total bilirubin \>2\*uln, or calculated creatinine clearance \<30 ml/min.

Keywords: anticoagulant
safety and immunogenicity of 9-valent human papillomavirus (9vhpv) vaccine coadministered with messenger ribonucleic acid (mrna)-1273 severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (covid-19) vaccine (v503-076)

Conditions: Papillomavirus Infections; Coronavirus Disease (COVID-19)

Summary: the purpose of this study to evaluate the safety and immunogenicity of a 2-dose regimen of 9vhpv vaccine, where the first dose is administered concomitantly with a first dose of a 2-dose regimen of mrna-1273 vaccine versus nonconcomitant administration of 9vhpv and mrna-1273 vaccines in boys and girls 9 to 11 years of age.


Eligibility criteria:
inclusion criteria: * has not yet had coitarche and does not plan on becoming sexually active during the vaccination period * participant or participant's legally acceptable representative can read, understand, and complete the electronic vaccination report card (evrc). exclusion criteria: * known allergy to any vaccine component * history of severe allergic reaction that required medical intervention * thrombocytopenia or any coagulation disorder * has a history of myocarditis or pericarditis * has a history of a clinical or microbiological diagnosis of covid-19 ≤90 days prior to day 1 visit or history of multisystem inflammatory syndrome in children (mis-c) at any time prior to day 1 visit * females only: participant is pregnant * currently immunocompromised, or been diagnosed with immunodeficiency * had a splenectomy * receiving or has received immunosuppressive therapies within the last year * received any immunoglobulin product or blood-derived product within 3 months * received a marketed hpv vaccine or has participated in an hpv vaccine clinical trial
sexuality after different mode of deliveris

Conditions: Sexual Dysfunction and the Mode of Deliveries

Summary: pregnancy and delivery usually affect the general women's quality of life. some studies have reported that sexual health may be affected by the mode of delivery. more than 70% of pregnant women prefer c-section due to several reasons point out the fear of pain and complications of vaginal delivery as the most common reasons. aim of the work: to explore the relationship between quality of life and the possible sexual dysfunction after normal vaginal in comparison to cesarean section deliveries.


Eligibility criteria:
inclusion criteria: * primiparas women who had been delivered by either vaginal or cesarean section about 6-12months. * all included women should be officially married exclusion criteria: * women with history of sexual dysfunction * women with history of any pelvic surgery apart from cesarean. * history of anti-depressive drug therapy. * history of genital prolapse * history of diabetes mellitus * loss of any family member or unfaveorouble neonatal outcome or childdeath * divorce experience * family problems and cases who were not interested in participation

Keywords: sexuality mode of delivery quality of life
multicenter study evaluating the efficacy of an intervention aimed at reducing the length of stay after transfemoral transcatheter aortic valve implantation

Conditions: Aortic Valve Stenosis; Cardiovascular Diseases

Summary: since the first implantation of a percutaneous aortic bioprosthesis (tavi) in 2002 (cribier et al. circulation 2002), tavi occupies an increasing place in the management of aortic stenosis (ar) . initially reserved for inoperable patients at high surgical risk, tavi is also recommended in patients at intermediate risk, especially when a femoral approach (tf) is possible (baumgartner et al. eur heart j. 2017). currently, there is no recommendation regarding length of stay after tavi and practices are extremely heterogeneous. despite the growing experience of centers, better patient selection and a reduction in complications, the length of stay after tavi remains very high in france. faced with the great disparity observed between the centers, efforts are necessary to educate the centers in order to further reduce the length of stay after tf-tavi. the aim of the study is to evaluate the effectiveness of an intervention based on training teams to reduce the length of stay after tf-tavi.


Eligibility criteria:
inclusion criteria: 1. patient over 18 years of age; 2. patient hospitalized for tf-tavi 3. patient affiliated or benefiting from a health insurance scheme 4. patient having read and understood the information letter and having signed the consent form. exclusion criteria: 1. proven pregnant woman (positive urine pregnancy test) or breastfeeding or absence of effective contraception (as defined by the who) or postmenopausal woman without confirmation diagnosis obtained (amenorrhea not medically induced for at least 12 months before the initiation visit) ; 1 2. person deprived of their liberty by an administrative or judicial decision or person placed under the protection of justice / guardianship or curatorship 3. history of illness or psychological or sensory abnormality likely to prevent the subject from fully understanding the conditions required for participating in the protocol or preventing him from giving his informed consent

Keywords: tavi aortic valve stenosis lenght-of-stay medico-economy
effects on atherosclerosis regression of ezetimibe or ezetimibe plus simvastatin; evaluated by fluorodeoxyglucose positron emission tomography (fdg-pet)

Conditions: Atherosclerosis

Summary: 18f-fluorodeoxyglucose (fdg) positron emission tomography (pet) is a promising tool for identifying and quantifying vascular inflammation within atherosclerotic plaques. therefore, in this study the investigators intend to compare the effect of ezetimibe monotherapy or ezetimibe plus statin combination therapy on the atherosclerosis regression using fdg-pet.


Eligibility criteria:
inclusion criteria: * hscrp \> 2 mg/l and ldl cholesterol \> 130 mm/dl exclusion criteria: * history of cardiovascular disease * diabetes * uncontrolled hypertension * active infection * previous anti-hyperlipidemic agents within 6 months * previous steroid or anti-inflammatory agents within 6 months * liver disease * renal disease

Keywords: high risk patients in atherosclerosis
eus prior to ercp in the positive setting of positive intraoperative cholangiogram (ioc) during cholecystectomy

Conditions: Calculi; Stenosis of Bile Duct

Summary: performing an eus prior to ercp in the setting of a positive intraoperative cholangiogram will identify and risk stratify patients for the presence of cbd stones and strictures.

during routine cholecystectomy, surgeons will often perform an intraoperative cholangiogram in an effort to define anatomical landmarks and ensure patency and drainage of the common bile duct. this involves injecting a radiopaque contrast medium into the biliary tree during the operation. occasionally contrast injection onto the common bile duct will reveal an abnormality and are deemed a "positive intraoperative cholangiogram" (positive ioc). these abnormalities can include the following: single or multiple stones; non-filling of the duodenum by contrast; stenosis or narrowing of the common bile duct (cbd). when discovered these findings are better addressed and treated endoscopically via endoscopic retrograde cholangiopancreatography (ercp). ercp's are considered the gold standard for the diagnosis and treatment of positive intraoperative cholangiograms. however, several studies have shown that 40-50% of patients who undergo an ercp after a "positive" ioc have a normal cholangiogram. reasons for this include spontaneous stone passage of the stone, dysmotility of the biliary tree, or poor quality, incomplete, or misinterpretation of the ioc. therefore ercp's are being performed when they could be avoided. ercp performance carries significant complications including pancreatitis (5-10%), bleeding, and perforation. ideally if a safer test to assess the bile duct could be performed immediately prior to the ercp to confirm the presence of the positive ioc findings, this would ensure that the ercp is being performed for therapeutic means thus avoiding unnecessary ercp's. eus is often performed prior to ercp's under the same sedation in our endoscopy unit. from 2005 to 2007, two hundred and twenty seven "combined eus and ercp procedure were performed.(unpublished internal data). our experience with "combined" eus and ercp procedures has demonstrated that performing an eus prior to an ercp will prolong the total procedure time less than 10 minutes with no significant increase in adverse events. performance of an eus prior to ercp to confirm biliary pathology after a "positive" ioc has never been studied in a rigorous fashion.

Eligibility criteria:
inclusion criteria: * subjects must be able to review and sign informed consent * cholecystectomy must have been performed within one month of enrollment * positive intraoperative cholangiogram * stone * multiple stones * stenosis * "non filling" of duodenum * dilated bile duct exclusion criteria: * cannot give and sign informed consent

Keywords: eus ercp intraoperative cholangiogram cholecystectomy common bile duct stones strictures stenosis duodenum dilated bile duct non-filling of the duodenum by contrast
to evaluate the food effect on pharmacokinetic profiles and safety in healthy volunteers

Conditions: Type 2 Diabetes Mellitus

Summary: this is a randomized, open-label, single dose, crossover, phase 1 trial to evaluate the food effect on pharmacokinetic profiles and safety of ckd-383 in healthy volunteers

participants were randomly assigned in a 1:1 ratio. theparticipants are prescribed oral administration of the appropriate ip(2 tablets in single dose: actual medication)

Eligibility criteria:
inclusion criteria: * healthy adults aged 19 to 54 years * bmi measurement result is 18.0 kg/m2 to 30 kg/m2 * written informed consent * other inclusion criteria, as defined in the protocol exclusion criteria: * who has taken drug metabolism enzyme induction and inhibitory drugs, such as barbitale drugs, within 30 days prior to the start of the trial (period 1 administration) * other exclusive criteria, as defined in the protocol
daw2020 on osa endotypic traits

Conditions: Obstructive Sleep Apnea (OSA)

Summary: obstructive sleep apnea (osa) is common and has major health implications but treatment options are limited. some osa patients with low arousal threshold wake up prematurely during an obstructive event and do not have time for spontaneous upper airway (ua) dilator muscle recruitment. as a consequence they are exposed to apnea and hypopnea cycling. in this protocol the investigators will test the effect of daw2020 administered before sleep on osa phenotype traits and osa severity during sleep.

two overnight sleep studies will be performed: a drug night and a placebo night. the patient will breath spontaneously (without cpap) for both nights. on the study nights, subjects will present to the laboratory in the evening and be instrumented with a full polysomnigraphy for monitoring sleep, physiological variables (endotypes), and respiratory events. a history and physical examination will be performed on each night prior to beginning the study, as will a urine pregnancy test in premenopausal women. daw2020 34 mg will be given 4 hours before lights out. subjects will sleep at least 50% of the night in the supine position. at least four hours of sleep with high quality signal acquisition will be required for a study to be judged adequate. after the first overnight study is completed, there will be a one-week washout period prior to crossing over to the other treatment.

Eligibility criteria:
inclusion criteria: * moderate-to-severe osa (ahi ≥ 15 events/hr) exclusion criteria: * all participants will be healthy and without major organ system disease that would preclude undergoing the physiological measurements. * use of medications expected to stimulate or depress respiration (including opioids, barbiturates, acetazolamide, doxapram, almitrine, theophylline, 4-hydroxybutanoic acid). * use of snris/ssris. * conditions likely to affect osa physiology: neuromuscular disease or other major neurological disorder, heart failure (also below), or any other unstable major medical condition. * sleep disordered breathing or respiratory disorders other than obstructive sleep apnea: * other sleep disorders: periodic limb movements (periodic limb movement arousal index \> 10/hr), narcolepsy, or parasomnias. * hypersensitivity to the study drug (angioedema or urticaria) * contraindications to daw2020 * use of medications that lengthen qtc interval * hypokaliemia, hypomagnesemia, uncontrolled thyroid disease * severe claustrophobia.